Adriana Fandiño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adriana Fandiño has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Guillermo Luis Chantada
Hospital Pereira Rossell Montevideo Uruguay
5 shared publications - Paula Schaiquevich
Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
4 shared publications - Ankit Singh Tomar
The Department of Ocular Tumor, Orbital Disease, and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, New York, NY, USA; The Department of Ophthalmology, Tulane University of Health Sciences, New Orleans, LA, USA
3 shared publications - Ashwin Mallipatna
Department of Ophthalmology & Vision Sciences, The Hospital for Sick Children, Toronto, Canada
3 shared publications - Denis P. Volodin
Ocular Oncology Department, The SN Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
3 shared publications - E. S. Kotova
National Medical Research Center Academician S.N. Fyodorov Intersectoral Scientific and Technical Complex “Eye microsurgery”, Ministry of Health of Russia
3 shared publications
Latest Publications
- Open Access
- 30 July 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (12) , 1409-1416
Diffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study
Background To determine the unique clinical characteristics and treatment outcomes of diffuse infiltrating retinoblastoma (DIR). Methods This international, multicentre, registry-based retrospective case series analysed pooled data from January 2001 to December 2013, including 132 eyes from 132 patients with DIR. Results Among 2854 eyes with retinoblastoma, 132 (4.6%; 95% CI, 3.9 to 5.5) had DIR. The median age at diagnosis for DIR patients was 24 months (IQR, 15–33), with no bilateral cases of DIR. The American Joint Committee on Cancer staging showed 4.5% cT2 and 95.5% cT3 categories, with no cT1 or cT4 cases. Clinical features associated with DIR included secondary glaucoma (67%), retinal detachment (38%), diffuse vitreous seeds (37%), anterior segment involvement (24%), vitreous haemorrhage (50%) and hyphema (6%). Primary enucleation was the predominant treatment (81%), while 19% initially received systemic chemotherapy, with 6% requiring subsequent enucleation. The 5-year Kaplan-Meier survival rate for cT3 DIR was 82% (95% CI, 78 to 86), significantly lower than the 94% (95% CI, 93 to 95) for cT3 non-DIR cases (pConclusions Approximately 1 in 20 patients with retinoblastoma had DIR, which often presented with glaucoma, anterior segment involvement or intraocular bleeding. DIR was more lethal than non-DIR cT3, with enucleation revealing high-risk pathology.
- 30 July 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (12) , 1409-1416
Open AccessDiffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study
Background To determine the unique clinical characteristics and treatment outcomes of diffuse infiltrating retinoblastoma (DIR). Methods This international, multicentre, registry-based retrospective case series analysed pooled data from January 2001 to December 2013, including 132 eyes from 132 patients with DIR. Results Among 2854 eyes with retinoblastoma, 132 (4.6%; 95% CI, 3.9 to 5.5) had DIR. The median age at diagnosis for DIR patients was 24 months (IQR, 15–33), with no bilateral cases of DIR. The American Joint Committee on Cancer staging showed 4.5% cT2 and 95.5% cT3 categories, with no cT1 or cT4 cases. Clinical features associated with DIR included secondary glaucoma (67%), retinal detachment (38%), diffuse vitreous seeds (37%), anterior segment involvement (24%), vitreous haemorrhage (50%) and hyphema (6%). Primary enucleation was the predominant treatment (81%), while 19% initially received systemic chemotherapy, with 6% requiring subsequent enucleation. The 5-year Kaplan-Meier survival rate for cT3 DIR was 82% (95% CI, 78 to 86), significantly lower than the 94% (95% CI, 93 to 95) for cT3 non-DIR cases (pConclusions Approximately 1 in 20 patients with retinoblastoma had DIR, which often presented with glaucoma, anterior segment involvement or intraocular bleeding. DIR was more lethal than non-DIR cT3, with enucleation revealing high-risk pathology.
- Open Access
- 30 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 933-945
Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma
- 30 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 933-945
Open AccessMetastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma
- Open Access
- 15 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 923-932
High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma
- 15 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 923-932
Open AccessHigh-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma
- Open Access
- 25 April 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (8) , e27086
Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina
Background: The feasibility and results of intraarterial chemotherapy, also termed ophthalmic artery chemosurgery (OAC), for retinoblastoma in less developed countries have seldom been reported.Procedure: A retrospective evaluation of a program of OAC in Argentina from 2010 to 2015.Results: Ninety‐seven eyes from 81 patients (61 bilateral) were analyzed. In 35 eyes, OAC was given as primary therapy and in 62 it was used for the treatment of tumors with partial response or those relapsing after systemic chemoreduction with focal therapy or external‐beam radiotherapy. Twenty‐two primarily treated eyes had group D and 13 groups B/C. A total of 400 procedures were carried out. Chemotherapy used included combinations of melphalan, carboplatin, and topotecan. There was no mortality associated with OAC. Toxicity included fever and neutropenia in five (1.25%), hypotension and bradycardia during anesthesia in two and femoral thrombosis in one, eyelid edema in nine, and neutropenia or thrombocytopenia in 28 cycles. With a median follow‐up of 48.7 months (range 12–79), the 3‐year probability of event‐free survival (pEFS) (enucleation and/or radiotherapy were considered events) was comparable for patients who received first‐line therapy and those treated at relapse (0.65 vs. 0.63, P = 0.5). In the former, the pEFS was 0.91 and 0.43 for groups B/C and D, respectively (P = 0.01). Two patients died of extraocular dissemination after refusal of enucleation.Conclusions: OAC was feasible with low toxicity. pEFS improved in all groups compared to the previous experience with systemic chemotherapy reducing the use of radiotherapy. The overall mortality associated with OAC is comparable to our previous experience with systemic chemoreduction.
- 25 April 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (8) , e27086
Open AccessFeasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina
Background: The feasibility and results of intraarterial chemotherapy, also termed ophthalmic artery chemosurgery (OAC), for retinoblastoma in less developed countries have seldom been reported.Procedure: A retrospective evaluation of a program of OAC in Argentina from 2010 to 2015.Results: Ninety‐seven eyes from 81 patients (61 bilateral) were analyzed. In 35 eyes, OAC was given as primary therapy and in 62 it was used for the treatment of tumors with partial response or those relapsing after systemic chemoreduction with focal therapy or external‐beam radiotherapy. Twenty‐two primarily treated eyes had group D and 13 groups B/C. A total of 400 procedures were carried out. Chemotherapy used included combinations of melphalan, carboplatin, and topotecan. There was no mortality associated with OAC. Toxicity included fever and neutropenia in five (1.25%), hypotension and bradycardia during anesthesia in two and femoral thrombosis in one, eyelid edema in nine, and neutropenia or thrombocytopenia in 28 cycles. With a median follow‐up of 48.7 months (range 12–79), the 3‐year probability of event‐free survival (pEFS) (enucleation and/or radiotherapy were considered events) was comparable for patients who received first‐line therapy and those treated at relapse (0.65 vs. 0.63, P = 0.5). In the former, the pEFS was 0.91 and 0.43 for groups B/C and D, respectively (P = 0.01). Two patients died of extraocular dissemination after refusal of enucleation.Conclusions: OAC was feasible with low toxicity. pEFS improved in all groups compared to the previous experience with systemic chemotherapy reducing the use of radiotherapy. The overall mortality associated with OAC is comparable to our previous experience with systemic chemoreduction.
- 1 June 1999
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (6) , 1847
Phase II Window of Idarubicin in Children With Extraocular Retinoblastoma
PURPOSE: The aim of this study was to evaluate in an upfront phase II study the response to idarubicin in children with extraocular retinoblastoma. PATIENTS AND METHODS: The starting dose of idarubicin was 15 mg/m2/d (days 1 and 2) weeks 0 and 3. After an interim evaluation, the dose was reduced to 10 mg/m2/d (days 1 and 2) weeks 0 and 3 because of hematopoietic toxicity. Response was evaluated at week 6. RESULTS: At the Hospital JP Garrahan (Buenos Aires, Argentina), 10 patients (five bilateral) were entered onto the study from 1995 to 1998. A total of 19 cycles were administered. Extraocular sites included orbit (n = 10), bone marrow (n = 3), bone (n = 1), lymph node (n = 1), and CNS (n = 1). The response rate was 60% (95% confidence interval, 30% to 90%). One complete response was achieved, in addition to five partial responses, two cases of stable disease, and two cases of progressive disease. All patients with bone marrow involvement achieved complete clearance of tumor cells. The patient with CNS disease had progressive disease. All patients had severe hematopoietic toxicity (grade 4 neutropenia and grade 3/4 thrombocytopenia after most cycles). Other toxicities included grade 2 diarrhea in 30%. No echocardiographic changes were detected. CONCLUSION: Idarubicin is active in extraocular retinoblastoma. The activity of this drug should be explored in future phase III studies.
- 1 June 1999
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (6) , 1847
Phase II Window of Idarubicin in Children With Extraocular Retinoblastoma
PURPOSE: The aim of this study was to evaluate in an upfront phase II study the response to idarubicin in children with extraocular retinoblastoma. PATIENTS AND METHODS: The starting dose of idarubicin was 15 mg/m2/d (days 1 and 2) weeks 0 and 3. After an interim evaluation, the dose was reduced to 10 mg/m2/d (days 1 and 2) weeks 0 and 3 because of hematopoietic toxicity. Response was evaluated at week 6. RESULTS: At the Hospital JP Garrahan (Buenos Aires, Argentina), 10 patients (five bilateral) were entered onto the study from 1995 to 1998. A total of 19 cycles were administered. Extraocular sites included orbit (n = 10), bone marrow (n = 3), bone (n = 1), lymph node (n = 1), and CNS (n = 1). The response rate was 60% (95% confidence interval, 30% to 90%). One complete response was achieved, in addition to five partial responses, two cases of stable disease, and two cases of progressive disease. All patients with bone marrow involvement achieved complete clearance of tumor cells. The patient with CNS disease had progressive disease. All patients had severe hematopoietic toxicity (grade 4 neutropenia and grade 3/4 thrombocytopenia after most cycles). Other toxicities included grade 2 diarrhea in 30%. No echocardiographic changes were detected. CONCLUSION: Idarubicin is active in extraocular retinoblastoma. The activity of this drug should be explored in future phase III studies.